[1] Xue R, Yang RX, Fan JG. Epidemiological trends and clinical characteristic of NAFLD/MAFLD in Asia. J Dig Dis,2022,23(7):354-357.
[2] 杨蕊旭,范建高. 非酒精性脂肪性肝病相关肝细胞癌流行病学与筛查. 实用肝脏病杂志,2022,25(2):153-156.
[3] Riazi K, Azhari H, Charette JH, et al. The prevalence and incidence of NAFLD worldwide: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol, 2022,7(9):851-861.
[4] Lazarus JV, Mark HE, Villota-Rivas M, et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? J Hepatol, 2022,76(4):771-780.
[5] Lazarus JV, Mark HE, Anstee QM, et al. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol,2022, 19(1):60-78.
[6] McPherson S, Armstrong MJ, Cobbold JF, et al. Quality standards for the management of non-alcoholic fatty liver disease (NAFLD): consensus recommendations from the British Association for the Study of the Liver and British Society of Gastroenterology NAFLD Special Interest Group. Lancet Gastroenterol Hepatol,2022,7(8):755-769. ,
[7] Duell PB, Welty FK, Miller M, et al. Nonalcoholic fatty liver disease and cardiovascular risk: a scientific statement from the American Heart Association. Arterioscler Thromb Vasc Biol,2022,42(6):e168-e185.
[8] Cusi K, Isaacs S, Barb D, et al. American Association of Clinical Endocrinology Clinical Practice Guideline for the Diagnosis and Management of Nonalcoholic Fatty Liver Disease in Primary Care and Endocrinology Clinical Settings: Co-Sponsored by the American Association for the Study of Liver Diseases (AASLD). Endocr Pract,2022,28(5):528-562.
[9] Udompap P, Therneau TM, Canning RE, et al. Performance of American Gastroenterological Association Clinical Care Pathway for the risk stratification of patients with nonalcoholic fatty liver disease in the US population. Hepatology,2022.
[10] 中国医药生物技术协会慢病管理分会. 肝硬化合并糖尿病患者血糖管理专家共识. 中华糖尿病杂志, 2022,14(8):749-763.
[11] Allen AM, Therneau TM, Ahmed OT, et al. Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial design. J Hepatol,2022, 77(5):1237-1245.
[12] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Gastroenterology,2020,158(7):1999-2014.e1.
[13] Zeng J, Fan JG. From NAFLD to MAFLD: Not just a change in the name. Hepatobiliary Pancreat Dis Int,2022,21(6):511-513.
[14] Méndez-Sánchez N, Fan JG, El-Kassas M, Girala M. MAFLD: A quick fact check. Liver Int,2022,42(12):2903-2906.
[15] Sarin SK, Eslam M, Fan JG, et al. MAFLD, patient-centred care, and APASL. Hepatol Int,2022,16(5):1032-1034.
[16] Younossi ZM, Paik JM, Al Shabeeb R, et al. Are there outcome differences between NAFLD and metabolic-associated fatty liver disease? Hepatology,2022, ,76(5):1423-1437.
[17] Gidener T, Dierkhising RA, Mara KC, et al. Change in serial liver stiffness measurement by magnetic resonance elastography and outcomes in NAFLD. Hepatology, 2023,77(1):268-274.
[18] Ajmera V, Kim BK, Yang K, et al. Liver Stiffness on Magnetic Resonance Elastography and the MEFIB Index and Liver-Related Outcomes in Nonalcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis of Individual Participants. Gastroenterology,2022,163(4):1079-1089.e5.
[19] de Franchis R, Bosch J, Garcia-Tsao G, et al. Baveno VII - Renewing consensus in portal hypertension. J Hepatol,2022,76(4):959-974.
[20] Shi YW, Fan JG. Current status and challenges in the drug treatment for fibrotic nonalcoholic steatohepatitis. Acta Pharmacol Sin,2022,43(5):1191-1199. doi: 10.1038/s41401-021-00822-1.
[21] Shi Y, Fan J. Therapeutic developments in metabolic dysfunction-associated fatty liver disease. Chin Med J (Engl),2022,135(9):1009-1018.
[22] Ezpeleta M, Gabel K, Cienfuegos S, et al. Effect of alternate day fasting combined with aerobic exercise on non-alcoholic fatty liver disease: A randomized controlled trial. Cell Metab,2023,35(1):56-70.e3.
[23] 孙超,范建高. 数字疗法在非酒精性脂肪性肝病治疗中的应用. 临床肝胆病杂志,2022,38(4):898-901.
[24] Alkhouri N, Herring R, Kabler H, et al. Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial. J Hepatol, 2022,77(3):607-618.
[25] Loomba R, Lawitz EJ, Frias JP, et al. Safety, pharmacokinetics, and pharmacodynamics of pegozafermin in patients with non-alcoholic steatohepatitis: a randomised, double-blind, placebo-controlled, phase 1b/2a multiple-ascending-dose study. Lancet Gastroenterol Hepatol,2023 ,8(2):120-132.
[26] Harrison SA, Manghi FP, Smith WB, et al. Licogliflozin for nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled, phase 2a study. Nat Med,2022,28(7):1432-1438.
[27] Takeshita Y, Honda M, Harada K, et al. Comparison of Tofogliflozin and Glimepiride Effects on Nonalcoholic Fatty Liver Disease in Participants With Type 2 Diabetes: A Randomized, 48-Week, Open-Label, Active-Controlled Trial. Diabetes Care,2022,45(9):2064-2075.
[28] Zeng RW, Yong JN, Tan DJH, et al. Meta-analysis: Chemoprevention of hepatocellular carcinoma with statins, aspirin and metformin. Aliment Pharmacol Ther,2023.
[29] 徐清扬,范建高. 肾素-血管紧张素系统抑制剂治疗非酒精性脂肪性肝病的研究进展. 肝脏,2022,27(11):1161-1163.
[30] Sun C, Fan JG. Editorial: changes of health-related quality of life associated with liver disease severity and its improvement after treatment in NAFLD. Aliment Pharmacol Ther,2023,57(2):257-258. |
